Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prothena Corp Public (PRTA) Research & Development (2016 - 2025)

Prothena Corp Public has reported Research & Development over the past 14 years, most recently at $14.6 million for Q4 2025.

  • Quarterly results put Research & Development at $14.6 million for Q4 2025, down 70.93% from a year ago — trailing twelve months through Dec 2025 was $134.9 million (down 39.4% YoY), and the annual figure for FY2025 was $134.9 million, down 39.4%.
  • Research & Development for Q4 2025 was $14.6 million at Prothena Corp Public, down from $28.9 million in the prior quarter.
  • Over the last five years, Research & Development for PRTA hit a ceiling of $64.1 million in Q1 2024 and a floor of $14.6 million in Q4 2025.
  • Median Research & Development over the past 5 years was $40.2 million (2022), compared with a mean of $39.8 million.
  • Biggest five-year swings in Research & Development: skyrocketed 121.54% in 2022 and later tumbled 70.93% in 2025.
  • Prothena Corp Public's Research & Development stood at $22.1 million in 2021, then skyrocketed by 67.15% to $36.9 million in 2022, then soared by 67.86% to $61.9 million in 2023, then decreased by 18.93% to $50.2 million in 2024, then tumbled by 70.93% to $14.6 million in 2025.
  • The last three reported values for Research & Development were $14.6 million (Q4 2025), $28.9 million (Q3 2025), and $40.5 million (Q2 2025) per Business Quant data.